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I would like to begin with a brief 
historical review of the subject of 
insulin antigenicity before I discuss 
its clinical significance. 
After the discovery of insulin, a 
little over four decades ago, some 
of the early preparations of insulin 
were relatively crude; and, as might 
be expected, a number of reactions 
occurred. In one of the first studies 
on insulin allergy utilizing pure 
crystalline insulin, Tuft ( 1928) 
established that it was the insulin 
itself which caused the skin reac-
tion and not the protein of the 
animal from which the insulin 
came. He further demonstrated 
that the material causing the skin 
reaction could be passively trans-
ferred to the skin of a normal 
individual by an intradermal injec-
tion of serum from the insulin-
allergic individual. He also showed 
the presence of a precipitin against 
insulin in the serum of the insulin-
allergic patient and demonstrated 
that the skin-sensitizing antibody 
remained in serum long after the 
precipitin was lost. He presented 
some evidence of an increased in-
sulin requirement in the patient 
when the precipitin was present 
and suggested that antibodies to 
insulin might be associated with 
insulin resistance. Other workers 
confirmed the fact that insulin was 
antigenic (Prout, 1962) and Sir 
Frederick Banting (1938) made the 
observation that psychiatric pa-
tients receiving insulin for shock 
therapy required more and more 
insulin to produce shock as time 
went on. He demonstrated that 
serum from these patients pro-
tected mice from convulsions when 
injected with insulin and later 
showed that the anti-insulin mate-
rial was located in the serum globu-
lin rather than the albumin. 
In 1944 Lowell defined the two 
kinds of antibodies against insulin, 
one a reagin which was heat labile 
and caused skin sensitization, and 
the other a heat-stable factor that 
prevented the hypoglycemic effect 
of insulin in vivo. 
Loveless and Cann (1955) 
showed that the heat-stable pre-
cipitin, the material with anti-
insulin effect in the intact animal, 
could in fact act as a blocking anti-
body for the skin-sensitizing reagin 
or the heat labile factor. These anti-
bodies traveled in two distinct areas 
on serum electrophoresis; the block-
ing antibody was a y-globulin, while 
the skin-sensitizing reagin traveled 
with the ft-globulins. 
Up to this time insulin was 
thought to be rarely associated with 
host reactions except for the occa-
sional local reaction to injection. 
It was Berson and his associates 
(1956) who showed that insulin 
antigenicity was a common phe-
nomenon. In patients who have 
been treated with intermediate or 
long-acting insulin, 80% have anti-
bodies in the serum that are meas-
ureable by techniques utilizing in-
sulin labelled with iodine 131 
(table 1) . 
Most of the clinical manifesta-
tions of the skin-sensitizing reagin 
are straightforward. Some of the 
rarer forms of sensitivity reaction 
attributable to insulin are difficult 
to substantiate (e.g. thrombocyto-
penia and gastrointestinal upset), 
but the skin reactions to insulin 
are not at all unusual. It is quite 
common to have local reactions to 
insulin in the first few weeks after 
insulin injections are started. In 
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TABLE l 
Insulin Antigenicity 
Skin Sensitivity I nsu Ii n Resistance 
Tuft (1928) Passive cutaneous Precipitin in serum 
transfer 
Banting (1938) Mouse protection by 
globulin of insulin-
resistant patient 
Lowell (1944) Heat-labile Heat stable. Reio-
ted to resistance. 
Possibly species 
specific 
Loveless and Separated with Separated with ')' -
Cann (1955) 13 -globulin globulin. "Blocking 
antibody" 
Berson (1956) Insulin-binding 
antibody 
TABLE 2 
Saturation in Insulin-binding Antibodies* 
Daily % Retention in Serum % Free Serum Insulin 
Insulin 60 min 5 min 
45 u/day 83 2. l 
90 u/day 72 3.3 
190 u/day 48 17.6 
*The relationship between dailh dose of insulin and saturation of 
insulin-binding antibodies is s own by these results. Free insulin 
is increased and becomes availqble for peripheral use. The in-
crease in daily insulin does not stimulate the over-production of 
antibodies in this type of patient. 
' 
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treating the patient with local reac-
tions, it is essential to be certain 
that the patient is injecting himself 
properly, that he is using a clean 
syringe and not injecting alcohol. 
Some physicians advocate that 
syringes and sites of injection be 
changed or that the insulin be 
warmed or even boiled; after sev-
eral weeks in which several tech-
niques have been tried, the local re-
actions subside. I suspect that this 
is not related to the ingenuity of 
the therapeutic maneuvers, but to 
time that has been consumed while 
waiting for the blocking antibodies 
to block the skin-sensitizing anti-
body. The patient has been de-
sensitized in precisely the same 
way that he has been desensitized 
for ragweed antigen, and the im-
portant part of therapy has been 
the continuation of injections until 
the patient is desensitized. 
Other phenomena at the injec-
tion site are of great interest al-
though it is not provi;!n that they 
are related to insulin antigenicity. 
These are the insulin-induced fat 
atrophy and/ or fat hypertrophy. 
Their cause remains an enigma. I 
have wondered whether insulin may 
become fixed to adipose tissue at 
the injection site and set up a tissue-
fixed antigen-antibody reaction with 
circulating antibodies. The time 
sequence suggests the validity of 
this possibility and on occasions a 
change to insulin of a different 
species has coincided with the end 
to fat atrophy. I am currently try-
ing to improve these demonstra-
tions and determine their signifi-
cance. These phenomena may well 
relate to the effect of insulin on fat 
metabolism, but thus far the rea-
sons for both fat atrophy and fat 
hypertrophy are obscure. 
The clinical significance of the 
heat-stable antibody to insulin 
found in the y-globulin is more 
easily determined. If we study the 
insulin-binding capacity of the 
serum of patients attending a dia-
betes clinic, we find that all patients 
taking intermediate insulin develop 
antibodies in six to eight weeks. 
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In general the titre of antibodies is 
low, and as a group the patients 
who have been on insulin the long-
est period of time have the higher 
titres. There is, of course, great 
variability. There are several inter-
esting exceptions to this generaliza-
tion. Insulin antibodies have been 
noted to disappear in patients re-
ceiving steroid for sarcoidosis. In 
other patients having the pro-
teinuria of Kimmelstiel-Wilson syn-
drome, insulin-binding antibodies 
are often lost along with other pro-
teins. Part of the insulin sensitivity 
seen in patients with this syndrome 
is probably related to the loss with 
the proteinuria of the buffering 
effect of the antibodies. In such pa-
tients the antibody titre seen in the 
serum is low even through the pa-
tient had been on insulin for more 
than 20 years. 
As Berson ( 1956) demonstrated, 
the presence of antibodies is readily 
shown in vivo. In patients with 
little or no antibody, there is rapid 
disappearance from the blood of in-
sulin labelled with 1''11 following an 
intravenous injection. Patients with 
insulin resistance show a marked 
prolongation of the half-time of 
labelled insulin in blood, and it is 
easy to show that the insulin J'31 
continues to circulate because it is 
bound to the y-globulin. 
Let me give an illustration of the 
clinical significance of this. A man 
previously controlled on 40 units 
of insulin developed ketoacidosis 
without obvious cause. He was 
treated successfully and discharged 
on his previous dose of 40 units 
daily. In a short time he returned 
again with ketoacidosis. An insulin 
effect had been obtained and the 
acidosis had been treated success-
fully, but this effect was promptly 
dissipated when he returned to his 
maintenance dose that was less than 
his daily needs. It was postulated 
that by saturating the circulating 
antibodies with larger daily doses 
of insulin the anti-insulin effect of 
his antibodies could be neutralized. 
It was first demonstrated that ap-
proximately 90% of the injected 
insulin J'31 remained in circulation 
for more than two hours while he 
was on an inadequate dose of in-
sulin. We then progressively raised 
his insulin dose, and he began to 
come under better control. Now 
we found that injected insulin 1'31 
disappeared from the blood more 
quickly, presumably because some 
of the binding sites of the insulin-
binding antibody were being occu-
pied by the daily dose of insulin 
he was receiving. As his insulin · 
dose was increased during the next 
week, he showed progressive short-
ening of the half-time of insulin in 
his blood and reciprocally a greater 
amount of the insulin was free to 
be utilized in the periphery. Insulin 
bound to antibody is preserved not 
only from peripheral use but also 
from peripheral degradation. The 
results of these studies of insulin-
1'31 over this period are shown in 
table 2. As the increased daily dose 
of insulin occupied more of the 
binding sites of the insulin-binding 
globulin, more of the daily insulin 
dose was free to exert its physio-
logical effects, and the control of 
his diabetes was thereby improved 
(Prout and Katims, 1959). 
Insulin resistance is not always 
related to insulin-binding antibod-
ies, of course, and in the differen-
tial diagnosis of this problem a 
number of other conditions must 
be considered (table 3). Obesity is 
usually associated with relative in-
sulin resistance. Obese patients who 
have never received insulin may 
require three or four times as much 
insulin to produce the same fall in 
blood glucose on an insulin toler-
ance test as their colleagues of 
normal weight. Obese diabetic sub-
jects who have not followed their 
prescribed diet and who hence are 
not controlled may require 50 to 
60 units daily at the onset to 
achieve control, although they are 
not dependent on insulin to prevent 
ketoacidosis. 
Moderate degrees of insulin re-
sistance are seen in acromegaly, 
Cushing's syndrome, hyperthyroid-
ism, and with steroid treatment. 
21 
Cyclic resistance associated with the 
menstrual cycle has been reported. 
None of these states are related to 
antibodies and are all relatively 
mild forms of resistance for the 
most part. 
Infection, of course, is the most 
common cause of insulin resistance 
and resistance quickly disappears 
as the infection is brought under 
control. Although an increase in 
insulin-binding antibodies with in-
fection would appear likely, we 
have not found a significant rise 
in circulating antibodies of any of 
these patients' studies, the most 
remarkable of whom has been re-
ported by Knowles and his col-
leagues (see Tucker et al., 1964) . 
Peripheral or tissue resistance to 
the effects of insulin has been postu-
lated and there are remarkable 
instances reported of severe resist-
ance on this basis that are unre-
lated to insulin antibodies (Field, 
1962). Another cause of apparent 
insulin resistance is the so-called 
Somogyi effect or paradoxical hy-
perglycemia (Somogyi, 1959). This 
refers to the patient who appears 
to need more insulin but in whom 
control becomes more difficult de-
spite the increase in his insulin 
dose. Hypoglycemia that often goes 
undetected is followed by rebound 
hyperglycemia and the patient and 
the physician are likely to increase 
the dose further unless the para-
doxical hyperglycemia is recog-
nized. The proper treatment is to 
decrease rather than increase the 
insulin dose after which the appar-
ent insulin resistance disappears. 
Evidence that the antibodies are 
not the result of high insulin dosage 
used in insulin resistance rather 
than a cause is difficult to find. I 
had an opportunity to study one 
patient who has helped to answer 
this question. A woman had had 
diabetes for a number of years and 
had developed insulin resistance 
with requirements of insulin ex-
ceeding 1,500 units per day. Her 
physician had told her that insulin 
was useless for her and the patient 
had discontinued her injections. 
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When seen, she had been off all 
treatment for four years. During 
this time, she had had constant 
glycosuria and had developed se-
vere peripheral neuropathy. We 
measured her insulin-binding capac-
ity after four years on no insulin 
and found an insignificant amount 
of binding still present, about 50 
microunits per ml. We began in-
sulin in relatively low doses and 
at the dose of 60 units of insulin 
per day, an insulin effect was seen. 
Her urine became free of glucose 
for the first time in four years. On 
the eighth day after beginning ther-
apy she was again found to be 
extremely resistant to insulin and 
impossible to control; her insulin-
binding antibodies had increased 
ten fold. An attempt was made 
immediately to saturate the high 
level of circulating antibodies by 
giving her 500 units of insulin in-
travenously which, under these spe-
cific circumstances, was quite safe 
and no effect of this insulin was 
seen on the blood glucose. Insulins 
from different species were tried as 
well as steroids; but in spite of 
this, on insulin in doses up to 1,500 
units daily, she did not respond. 
After oral agents became available, 
hyperglycemia was controlled to 
some degree. This patient was found 
responsive to insulin in moderate 
doses before the recurrence of in-
sulin resistance. Antibodies devel-
oped before massive doses of in-
sulin were used and resistance 
became clinically significant with 
the rapid rise of antibodies. 
What steps do we take when con-
fronted with an insulin-resistant pa-
tient? Let us assume that the ob-
vious causes of insulin resistance, 
such as obesity or infection, have 
been ruled out and that the insulin 
requirements are in excess of 200 
units per day. First we should 
determine whether the patient is 
really insulin dependent. The two 
phenomena do not necessarily go 
hand in hand. Insulin dependency 
is related to the presence or ab-
sence of retrievable insulin from 
the pancreas. Insulin resistance is 
related to response to injected 
insulin and may develop in patients 
still capable of responding to oral 
agents. The patient just described 
illustrates this. If the patient is not 
insulin dependent, an oral hypo-
glycemic agent may be effective. If 
this fails, and insulin therapy is 
mandatory, one may attempt to 
saturate the antibodies by rapidly 
increasing the insulin dose as I 
have described above. This can 
sometimes be best accomplished by 
using crystalline insulin in multiple 
doses throughout the day; this is 
always more effective in patients 
with a large amount of insulin-
binding antibody than is intermedi-
ate or long-acting insulin. If this 
does not succeed, insulin from dif-
ferent species, usually pork insulin, 
can be tried. 
TABLE 3 
Differential Diagnosis of Insulin Resistance 
I) Obesity 
2) Endocrine states: 
a ) acromegaly 
b) Cushing's syndrome 
c ) hyperthyroidism 
d) menstrual cycle 
3) Peri pheral resistanc e 
4) Infection 
5) Antibodies to insulin 
TABLE 4 
Relative resistance easily 
Mild resistance. Usually 
less than 100 units/ day 
of insulin required unless 
other complications ore 
present. 
Unusual condition diffi-
cult to prove . Very high 
quantities of insulin used 
with little effect. 
Commonest form of re-
sistance, Rapidly rever-
sed with treatment of 
infection . 
De monstration by in v ivo 
or in vitro techniques. 
Treatment of Insulin Resistance Related to 
Insulin-binding Antibodies 
l) Determine insulin dependency 
2) Antibody saturation 
3) Change to insulin of another species 
(pork, f ish) 
4) Adrenal steroids or ACTH 
5) Anti-metabolites not recommended 
6) Time and continued treatment with 
insulin in crystalline form 
Antimetabolites such as 6-mer-
captopurine theoretically might 
help these patients by suppressing 
formation of antibodies. This has 
been tried on several occasions 
without any great success (Meri-
mee, 1965). 
Adrenal steroids are relatively 
low on the treatment list for insu-
lin resistance. It is better to have 
a patient maintained on 300 units 
of insulin a day than to have him 
on steroids for life. Steroids can 
sometimes be used to decrease 
insulin resistance but the resistance 
frequently returns when steroids 
are tapered and stopped, and long-
term steroid treatment may be re-
quired. Steroids must be used, as 
elsewhere in medicine, with cir-
cumspection. 
Not the least important in the 
treatment of insulin resistance due 
to insulin binding antibodies is the 
use of time. If the resistant patient 
can be maintained on a high dose 
of insulin required for control, 
eventually the resistance may dis-
appear in the same way it came, 
indeed, with less explanation. Con-
tinuation of insulin, especially as 
crystalline or regular insulin, is 
essential in such patients (table 4). 
Interruption of insulin therapy may 
in fact be one of the settings in 
which relative insulin resistance 
occurs when insulin is restarted. 
Thus we have seen that evidence 
of insulin antigenicity in one or 
more forms is present in most in-
dividuals receiving intermediate in-
sulins for six weeks or longer. A 
number of clinical manifestations 
of insulin antigenicity and their 
treatment have been discussed. 
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